US 11,865,126 B2
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
Derek John Londesbrough, Hartlepool (GB); Christopher Brown, Gateshead (GB); Julian Scott Northen, South Shields (GB); Gillian Moore, Sedgefield (GB); Hemant Kashinath Patil, Surrey (GB); David E. Nichols, Chapel Hill, NC (US); Megan Croal, Altrincham (GB); Hans Åke Eriksson, Altrincham (GB); George Goldsmith, Altrincham (GB); Molly Tabitha Hickey, Altrincham (GB); Shaun Hurley, Altrincham (GB); Ekaterina Malievskaia, Altrincham (GB); Lindsey Marwood, Altrincham (GB); Drummond E-Wen Joe Mcculloch, Altrincham (GB); Laurie Emma Medhurst, Altrincham (GB); Nathan Poulsen, Princeton Junction, NJ (US); Aslihan Selimbeyoglu, Altrincham (GB); Anaïs Soula, Altrincham (GB); Amanda Tan Shuxiang, Altrincham (GB); Manon Cecile Elisabeth Veraart, Altrincham (GB); Tobias Patrick Whelan, Altrincham (GB); Lars Christian Wilde, Altrincham (GB); and Stephen Wright, Altrincham (GB)
Assigned to Compass Pathfinder Limited, Altrincham (GB)
Filed by Compass Pathfinder Limited, Altrincham (GB)
Filed on Jun. 15, 2023, as Appl. No. 18/210,526.
Application 18/210,526 is a continuation of application No. 18/077,876, filed on Dec. 8, 2022, granted, now 11,738,035.
Application 18/077,876 is a continuation of application No. 17/540,962, filed on Dec. 2, 2021, granted, now 11,564,935, issued on Jan. 31, 2023.
Application 17/540,962 is a continuation of application No. 17/604,619, previously published as PCT/IB2020/053687, filed on Apr. 17, 2020.
Claims priority of provisional application 62/946,159, filed on Dec. 10, 2019.
Claims priority of provisional application 62/893,611, filed on Aug. 29, 2019.
Claims priority of provisional application 62/893,110, filed on Aug. 28, 2019.
Claims priority of provisional application 62/835,479, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,472, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,450, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,465, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,485, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,458, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,476, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,474, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,484, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,481, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,478, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,449, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,477, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,464, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,480, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,482, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,460, filed on Apr. 17, 2019.
Prior Publication US 2023/0330117 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/661 (2006.01); A61P 25/00 (2006.01); A61P 25/20 (2006.01); A61P 25/28 (2006.01); A61P 25/22 (2006.01); A61P 25/04 (2006.01); A61P 25/08 (2006.01); A61P 25/16 (2006.01); C07F 9/572 (2006.01); A61K 9/00 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/661 (2013.01); A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 25/08 (2018.01); A61P 25/16 (2018.01); A61P 25/20 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); C07F 9/5728 (2013.01); C07B 2200/13 (2013.01)] 30 Claims
 
1. A method of treating an anxiety disorder in a patient, the method comprising orally administering a therapeutically effective amount of an oral dosage form, wherein the oral dosage form comprises:
crystalline psilocybin characterized by XRPD peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1° 2θ, wherein crystalline psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis; and
a pharmaceutically acceptable excipient.